Allergan plc Company Profile (NYSE:AGN)

About Allergan plc

Allergan plc logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: AGN
  • CUSIP: 01849010
Key Metrics:
  • Previous Close: $245.37
  • 50 Day Moving Average: $228.83
  • 200 Day Moving Average: $222.62
  • 52-Week Range: $375,080,000.00 - $184.50
  • Trailing P/E Ratio: 6.43
  • Foreward P/E Ratio: 13.80
  • P/E Growth: 1.13
  • Market Cap: $92.03B
  • Outstanding Shares: 375,080,000
  • Beta: 1.07
  • Net Margins: 100.04%
  • Return on Equity: 7.21%
  • Return on Assets: 4.00%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 3.95%
  • Quick Ratio: 3.86%
Additional Links:
Companies Related to Allergan plc:

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:AGN) (?)
Ratings Breakdown: 6 Hold Ratings, 19 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $274.37 (11.82% upside)

Analysts' Ratings History for Allergan plc (NYSE:AGN)
DateFirmActionRatingPrice TargetDetails
2/22/2017Piper Jaffray CompaniesSet Price TargetHold$205.00View Rating Details
2/14/2017RBC Capital MarketsSet Price TargetBuy$279.00View Rating Details
2/14/2017Credit Suisse GroupReiterated RatingBuy$274.00View Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00View Rating Details
2/7/2017MizuhoReiterated RatingBuy$273.00 -> $275.00View Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Reiterated RatingPositive -> Buy$240.00 -> $250.00View Rating Details
12/25/2016Sanford C. BernsteinSet Price TargetBuy$275.00View Rating Details
12/23/2016Bank of America CorpReiterated RatingBuy$280.00View Rating Details
12/23/2016Deutsche Bank AGReiterated RatingBuy$245.00 -> $247.00View Rating Details
12/6/2016ArgusReiterated RatingBuy$340.00 -> $260.00View Rating Details
12/5/2016J P Morgan Chase & CoSet Price TargetBuy$300.00View Rating Details
11/21/2016William BlairReiterated RatingMarket PerformView Rating Details
11/3/2016Morgan StanleyLower Price TargetOverweight$300.00 -> $274.00View Rating Details
11/3/2016Royal Bank of CanadaLower Price TargetOutperform$300.00 -> $279.00View Rating Details
10/31/2016Barclays PLCReiterated RatingEqual Weight$250.00View Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
6/10/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
5/29/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00View Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00View Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00View Rating Details
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00View Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Allergan plc (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.65$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.18$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.38$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
2/4/2015Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
10/27/2014Q314$1.68$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
5/7/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan plc (NYSE:AGN)
Current Year EPS Consensus Estimate: $16.04 EPS
Next Year EPS Consensus Estimate: $17.78 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$2.91$3.17$3.04
Q2 20161$3.29$3.29$3.29
Q3 20161$3.55$3.55$3.55
Q4 20161$3.76$3.76$3.76
Q1 20172$3.43$3.55$3.49
Q2 20172$3.85$4.08$3.97
Q3 20172$4.16$4.20$4.18
Q4 20172$4.35$4.46$4.41
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan plc (NYSE:AGN)
Annual Dividend:$2.80
Dividend Yield:1.14%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:7.48% (Based on Trailing 12 Months of Earnings)
17.46% (Based on Current Year Consensus EPS Estimate)
15.75% (Based on Next Year Consensus EPS Estimate)

Dividend History for Allergan plc (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Allergan plc (NYSE:AGN)
Insider Ownership Percentage: 0.27%
Institutional Ownership Percentage: 86.40%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Allergan plc (NYSE:AGN)
News IconAllergan plc (AGN), Quintiles IMS Holdings, Inc. (Q) Stock Eyes Ahead of Earnings - The USA Commerce (NYSE:AGN) - February 24 at 3:22 PM logoNASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 (NYSE:AGN) - February 24 at 3:22 PM logoAllergan's Saunders: No interest in Valeant (NYSE:AGN) - February 22 at 7:41 PM
News IconAnalyst's Proposition on Allergan plc (AGN), Hologic, Inc. (HOLX) - The USA Commerce (NYSE:AGN) - February 22 at 11:41 AM logoZELTIQ: A Great Addition To Allergan's Aesthetics Franchise - Seeking Alpha (NYSE:AGN) - February 21 at 3:39 PM
News IconLookout for Price Target? Allergan plc (AGN), Xilinx, Inc. (XLNX) - StockNewsJournal (NYSE:AGN) - February 21 at 3:39 PM logoStull, Stull & Brody is Investigating Claims on Behalf of Allergan's (NYSE:AGN) 401(k) Plan (NYSE:AGN) - February 17 at 6:51 PM
News IconTraders Secrets on The Hartford Financial Services Group, Inc. (HIG), Allergan plc (AGN) - StockNewsJournal (NYSE:AGN) - February 17 at 6:43 PM logoStull, Stull & Brody is Investigating Claims on Behalf of Allergan’s (NYSE:AGN) 401(k) Plan (NYSE:AGN) - February 17 at 6:43 PM logoMedicines360 And Allergan Announce Partnership With Health Centers To Help Address Unintended Pregnancies In Areas Impacted By Zika (NYSE:AGN) - February 16 at 8:27 PM logoTepper's Appaloosa Fund Continues Bet on Drug Companies in Q4 2016 (NYSE:AGN) - February 16 at 8:27 PM
News IconA Look Ahead For 2 Stocks: Allergan plc (AGN), Host Hotels & Resorts, Inc. (HST) - Post Analyst (NYSE:AGN) - February 16 at 3:26 PM
News IconRevenue Approximations Analysis: Allergan plc (AGN), CenterPoint Energy, Inc. (CNP) - StockNewsJournal (NYSE:AGN) - February 16 at 3:26 PM logoAllergan's Roll-Up Is Not Breaking Even (SEC Letter Response) - Seeking Alpha (NYSE:AGN) - February 16 at 3:26 PM
News IconImpact of Brokerage Rating on Allergan PLC.(AGN) - Highland Mirror (NYSE:AGN) - February 15 at 1:43 AM
News IconThe The Allergan PLC (NYSE:AGN) - February 14 at 8:42 PM logoTeva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance (NYSE:AGN) - February 14 at 8:42 PM logoToday's Research Reports on Stocks to Watch: Teva Pharmaceutical Industries and Allergan (NYSE:AGN) - February 14 at 8:42 PM logoBets on financials, pharma power U.S. hedge funds' strong start to year (NYSE:AGN) - February 14 at 8:42 PM logoDavid Tepper Increases Wagers on Drug Companies (NYSE:AGN) - February 14 at 8:41 PM logoWhat the Smart Money's buying (NYSE:AGN) - February 14 at 8:41 PM logoAllergan: Be Positive On The Zeltiq Deal - Seeking Alpha (NYSE:AGN) - February 14 at 1:19 AM logoAllergan to buy Zeltiq Aesthetics for about $2.48 billion - Reuters (NYSE:AGN) - February 13 at 8:18 PM logoAllergan's Chief R&D Officer Talks Avycaz, Assembly Biosciences And 6 'Potential Blockbusters' In The Pipeline - Benzinga (NYSE:AGN) - February 13 at 8:18 PM logoAllergan Paying Nearly $2.5 Billion for ZELTIQ (NYSE:AGN) - February 13 at 8:18 PM logoAllergan's Chief R&D Officer Talks Avycaz, Assembly Biosciences And 6 'Potential Blockbusters' In The Pipeline (NYSE:AGN) - February 13 at 4:23 PM logoBotox-maker Allergan is betting that zapping your fat is worth $4 billion (NYSE:AGN) - February 13 at 2:52 PM logoAllergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion - Reuters (NYSE:AGN) - February 13 at 1:25 PM logoWhy Zeltiq Aesthetics Stock Is Surging Higher Today (NYSE:AGN) - February 13 at 1:00 PM logoZeltiq Aesthetics Inc (ZLTQ) Stock Soars on$2.5B Allergan (AGN) Deal (NYSE:AGN) - February 13 at 12:09 PM logoZeltiq Aesthetics Saw Aggressive Buying Ahead Of Allergan Takeover (NYSE:AGN) - February 13 at 11:48 AM logoAllergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq - (NYSE:AGN) - February 13 at 11:25 AM logoAllergan to spend $2.48 billion to buy CoolSculpting provider Zeltiq (NYSE:AGN) - February 13 at 10:22 AM
News IconAllergan is buying a fat-freezing company for $2.5 billion - Business Insider (NYSE:AGN) - February 13 at 9:53 AM logoZeltiq shares leap 12% in premarket on news of takeover by Allergan (NYSE:AGN) - February 13 at 9:53 AM logoAllergan to buy body contouring tech company for about $2.48 billion (NYSE:AGN) - February 13 at 9:31 AM logoAllergan takes out ZELTIQ for $2.47B (NYSE:AGN) - February 13 at 8:52 AM logoAllergan buying Zeltiq Aesthetics for nearly $2.5 bln (NYSE:AGN) - February 13 at 8:29 AM
News IconNotable Stock Analysts Ratings: Allergan plc (NYSE:AGN) (NYSE:AGN) - February 13 at 1:25 AM logoAllergan Plc :AGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017 (NYSE:AGN) - February 11 at 1:53 AM logoAASLD Foundation's Liver Disease Research and Education Initiatives Bolstered by Significant Donation from Allergan (NYSE:AGN) - February 11 at 1:53 AM
News IconEquity Perception: Analyst's Indicator Review for Texas Instruments Incorporated (TXN), Allergan plc (AGN) - The USA Commerce (NYSE:AGN) - February 10 at 3:51 PM
News IconThe Case for and Against Allergan plc (AGN) - StockNewsJournal (NYSE:AGN) - February 10 at 3:51 PM logoAllergan Plc :AGN-US: Earnings Analysis: 2016 By the Numbers : February 10, 2017 (NYSE:AGN) - February 10 at 3:51 PM logoIntercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split (NYSE:AGN) - February 10 at 3:51 PM logoAllergan to Present at The Leerink Partners 6th Annual Global Healthcare Conference (NYSE:AGN) - February 9 at 8:27 PM
News IconQ1 2017 Earnings Estimate for Allergan PLC. Issued By Leerink Swann (AGN) (NYSE:AGN) - February 9 at 1:29 AM
News IconThe Key Figures To Watch From Allergan plc (NYSE:AGN) Earnings (NYSE:AGN) - February 9 at 1:29 AM logoEdited Transcript of AGN earnings conference call or presentation 8-Feb-17 1:30pm GMT (NYSE:AGN) - February 9 at 1:29 AM logoWhat's Next For Allergan? How About More Acquisitions and a Dividend! (NYSE:AGN) - February 9 at 1:29 AM


What is Allergan plc's stock symbol?

Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan plc pay dividends? What is the dividend yield for Allergan plc?

Allergan plc declared a quarterly dividend on Wednesday, November 2nd. Investors of record on Tuesday, February 28th will be paid a dividend of $0.70 per share on Tuesday, March 28th. This represents a $2.80 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date is Friday, February 24th. This is a positive change from Allergan plc's previous quarterly dividend of $0.05.

Where is Allergan plc's stock going? Where will Allergan plc's stock price be in 2017?

25 brokers have issued 12-month price objectives for Allergan plc's stock. Their forecasts range from $205.00 to $330.00. On average, they anticipate Allergan plc's share price to reach $274.37 in the next year.

When will Allergan plc announce their earnings?

Allergan plc is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

What are analysts saying about Allergan plc stock?

Here are some recent quotes from research analysts about Allergan plc stock:

  • Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
  • According to Zacks Investment Research, "Allergan is reshaping its portfolio through acquisitions/divestitures. Allergan has been pretty active on the acquisition front and made six new product acquisitions in the third quarter. With the Allergan, Inc. acquisition, the company finds itself among the top 10 pharmas worldwide based on sales. Moreover, with the closing of the Teva deal, the company’s restructured and simplified business is encouraging. As a result, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. Also, Allergan’s shares outperformed the generic industry in past six months. However, while we remain optimistic about the company’s growth prospects, the company is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us." (1/3/2017)

  • Citigroup Inc. analysts commented, "should not be overlooked."Allergan's first-quarter adjusted earnings of $3.04 per share topped the Street's estimate of $3.01. The company's adjusted top line grew 48.1 percent to $3.9 billion, yet came in below consensus view of $3.95 billion. Related Link: Allergan Q1 Adjusted Earnings Beat Predictions"While AGN's 1Q16 revenues missed consensus expectations, we note the strong performance of key brands (Botox, Linzess, Lumigan, Alphagan, dermal fillers) vs. Street expectations," analyst Liav Abraham wrote in a note.Share Buyback ProgramThe Botox maker also authorized a new $10 billion share buyback program, of which $4 billion–$5 billion is expected to be executed over the next four to six months."While the share buyback signals management's view regarding the stock's valuation, it also preserves meaningful optionality for execution on incremental business development opportunities," Abraham noted.A Look ForwardLooking ahead, Allegan still sees adjusted revenues of $17 billion for the current year. That included branded net revenue of $15 billion. The Street analysts expect the company to deliver $16.88 billion revenue. The company indicated that its non-GAAP R&D is expected to be $1.5 billion."While the positive development of a share buyback may be moderated by the 1Q16 top-line miss, we maintain our view regarding the quality of AGN's core assets and the company's growth profile vs. the peer group," (5/11/2016)

Who owns Allergan plc stock?

Allergan plc's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.75%), Appaloosa LP (1.14%), Janus Capital Management LLC (1.04%), Baupost Group LLC MA (0.92%), Edgewood Management LLC (0.67%) and Dimensional Fund Advisors LP (0.42%). Company insiders that own Allergan plc stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro.

Who sold Allergan plc stock? Who is selling Allergan plc stock?

Allergan plc's stock was sold by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Bain Capital Public Equity Management LLC, State Street Corp, DSM Capital Partners LLC, Institutional Capital LLC, Levin Capital Strategies L.P., Handelsbanken Fonder AB and Bluestein R H & Co..

Who bought Allergan plc stock? Who is buying Allergan plc stock?

Allergan plc's stock was purchased by a variety of institutional investors in the last quarter, including Appaloosa LP, Edgewood Management LLC, Baupost Group LLC MA, Russell Investments Group Ltd., Janus Capital Management LLC, Iridian Asset Management LLC CT, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main and NWQ Investment Management Company LLC. Company insiders that have bought Allergan plc stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro.

How do I buy Allergan plc stock?

Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Allergan plc stock cost?

One share of Allergan plc stock can currently be purchased for approximately $245.37.

Allergan plc (NYSE:AGN) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Allergan plc (NYSE:AGN)

Earnings History Chart

Earnings by Quarter for Allergan plc (NYSE:AGN)

Dividend History Chart

Dividend Payments by Quarter for Allergan plc (NYSE:AGN)

Last Updated on 2/26/2017 by Staff